Reuters logo
BRIEF-Oncolytics announces successful end-of-Phase 2 meeting with FDA for reolysin
September 18, 2017 / 11:17 AM / 3 months ago

BRIEF-Oncolytics announces successful end-of-Phase 2 meeting with FDA for reolysin

Sept 18 (Reuters) - Oncolytics Biotech Inc

* Oncolytics Biotech Inc - announces successful end-of-Phase 2 meeting with FDA for reolysin in metastatic breast cancer

* Oncolytics Biotech Inc - FDA provided guidance that if study achieves its primary endpoint, then it will be only study required for BLA approval Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below